牛熊異動 | 業績好於預期,蒙牛認購證大升超100%
今早開盤,蒙牛乳業(02319.HK)持續走高,截至發稿升超8%,相關衍生品蒙牛摩通零十購A(20131.HK)升超100%。
蒙牛乳業本週三公佈中期業績,截至2020年6月30日止6個月,公司收入爲人民幣375.335億元,同比減少 5.8%;公司擁有人應佔利潤爲人民幣12.115億元,同比下降41.7%;每股盈利爲人民幣0.309元。高盛隨後發研報指,蒙牛中期淨利潤降幅 41.7%,好於其預先宣佈的45-60%的下降幅度。公司次季銷售額同比回升19%,銷售額與首季持平,而公司次季淨利潤爲12.85億元人民幣,同比升86%。高盛認爲,蒙牛次季的恢復優於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.